PriceTargets.com logo

Axonics - AXNX Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$70.98 As of 11/15/2024 01:00 AM ET
+0 (0.00%)
Get New Axonics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AXNX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AXNX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Axonics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $70.98.

This chart shows the closing price for AXNX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 contributing investment analysts is to hold stock in Axonics. This rating has held steady since December 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
7/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/19/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/8/2024Needham & Company LLCReiterated RatingHold
8/5/2024Needham & Company LLCReiterated RatingHold
5/6/2024Needham & Company LLCReiterated RatingHold
2/29/2024Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$71.00
1/17/2024Needham & Company LLCReiterated RatingBuy ➝ Hold
1/12/2024Truist FinancialReiterated RatingBuy ➝ Hold$73.00 ➝ $71.00
1/12/2024CL KingReiterated RatingBuy ➝ Neutral
1/12/2024Piper SandlerReiterated RatingOverweight ➝ Neutral$75.00 ➝ $71.00
1/12/2024Leerink PartnersReiterated RatingOutperform ➝ Market Perform$71.00
1/10/2024Wells Fargo & CompanyReiterated RatingOverweight ➝ Equal Weight$68.00 ➝ $71.00
1/9/2024Wolfe ResearchDowngradeOutperform ➝ Peer Perform
12/22/2023Truist FinancialBoost TargetBuy ➝ Buy$65.00 ➝ $73.00
10/31/2023Piper SandlerLower TargetOverweight ➝ Overweight$84.00 ➝ $75.00
10/31/2023Morgan StanleyLower TargetOverweight ➝ Overweight$76.00 ➝ $69.00
10/31/2023Needham & Company LLCLower TargetBuy ➝ Buy$76.00 ➝ $63.00
10/16/2023Leerink PartnrsReiterated RatingOutperform
10/16/2023Leerink PartnersInitiated CoverageOutperform$70.00
7/28/2023Needham & Company LLCBoost TargetBuy$73.00 ➝ $76.00
7/28/2023Robert W. BairdBoost Target$69.00 ➝ $70.00
7/28/2023KeyCorpBoost TargetOverweight$70.00 ➝ $71.00
7/18/2023Robert W. BairdInitiated CoverageOutperform$69.00
7/14/2023MizuhoReiterated RatingBuy ➝ Buy$75.00
7/13/2023KeyCorpInitiated CoverageOverweight$70.00
7/12/2023Royal Bank of CanadaLower Target$85.00 ➝ $75.00
5/23/2023CL KingInitiated CoverageBuy$75.00
5/2/2023Needham & Company LLCBoost Target$71.00 ➝ $73.00
4/17/2023Truist FinancialLower TargetBuy$82.00 ➝ $73.00
4/13/2023MizuhoInitiated CoverageBuy$75.00
3/24/2023Needham & Company LLCUpgradeHold ➝ Buy$71.00
1/6/2023Morgan StanleyLower TargetOverweight$92.00 ➝ $76.00
12/20/2022Truist FinancialLower TargetBuy$90.00 ➝ $82.00
11/1/2022Truist FinancialBoost TargetBuy$80.00 ➝ $90.00
11/1/2022Wells Fargo & CompanyBoost TargetOverweight$83.00 ➝ $90.00
10/21/2022Royal Bank of CanadaInitiated CoverageOutperform$85.00
10/17/2022Truist FinancialLower TargetBuy$85.00 ➝ $80.00
10/12/2022Jefferies Financial GroupInitiated CoverageHold$75.00
10/11/2022Morgan StanleyBoost TargetOverweight$80.00 ➝ $92.00
10/10/2022Needham & Company LLCDowngradeBuy ➝ Hold
10/5/2022Piper SandlerBoost TargetOverweight$82.00 ➝ $84.00
8/2/2022Morgan StanleyBoost TargetOverweight$73.00 ➝ $80.00
8/2/2022Needham & Company LLCBoost TargetBuy$60.00 ➝ $77.00
8/2/2022Truist FinancialBoost TargetBuy$75.00 ➝ $85.00
8/2/2022Wells Fargo & CompanyBoost TargetOverweight$80.00 ➝ $87.00
8/2/2022Piper SandlerBoost TargetOverweight$77.00 ➝ $82.00
7/20/2022Truist FinancialBoost TargetBuy$64.00 ➝ $75.00
5/6/2022Piper SandlerBoost Target$75.00 ➝ $77.00
4/5/2022Wolfe ResearchInitiated CoverageOutperform$69.00
3/8/2022Needham & Company LLCReiterated RatingBuy$62.00
3/2/2022Bank of AmericaInitiated CoverageBuy ➝ Buy
2/25/2022Leerink PartnersBoost TargetOutperform$60.00 ➝ $65.00
2/25/2022Morgan StanleyLower TargetOverweight$73.00 ➝ $69.00
1/7/2022Morgan StanleyLower TargetOverweight$74.00 ➝ $73.00
12/14/2021Needham & Company LLCLower TargetBuy$71.00 ➝ $62.00
11/5/2021Needham & Company LLCLower TargetBuy$78.00 ➝ $71.00
11/5/2021Leerink PartnersBoost TargetOutperform$80.00 ➝ $85.00
11/5/2021Piper SandlerLower TargetOverweight$78.00 ➝ $75.00
9/21/2021Needham & Company LLCReiterated RatingBuy$78.00
8/9/2021Morgan StanleyBoost TargetOverweight$62.00 ➝ $74.00
8/6/2021BarclaysBoost TargetOverweight$74.00 ➝ $79.00
8/6/2021Piper SandlerBoost TargetOverweight$75.00 ➝ $78.00
7/20/2021Leerink PartnersReiterated RatingOutperform
7/12/2021BarclaysInitiated CoverageOverweight$74.00
6/28/2021Needham & Company LLCBoost TargetBuy$72.00 ➝ $78.00
5/7/2021Needham & Company LLCBoost TargetBuy$71.00 ➝ $72.00
5/7/2021Morgan StanleyBoost TargetOverweight$58.00 ➝ $62.00
5/7/2021Piper SandlerReiterated RatingOverweight$70.00 ➝ $75.00
5/3/2021Piper SandlerBoost TargetOverweight$70.00 ➝ $75.00
3/24/2021Needham & Company LLCBoost TargetPositive ➝ Buy$66.00 ➝ $71.00
3/12/2021Piper SandlerBoost TargetPositive ➝ Overweight$64.00 ➝ $68.00
2/26/2021Needham & Company LLCBoost TargetBuy$62.00 ➝ $66.00
1/26/2021Robert W. BairdBoost TargetOutperform$58.00 ➝ $65.00
1/26/2021Piper SandlerBoost TargetOverweight$57.00 ➝ $64.00
1/7/2021Morgan StanleyBoost TargetOverweight$53.00 ➝ $58.00
11/5/2020Truist FinancialBoost Target$50.00 ➝ $58.00
11/5/2020Wells Fargo & CompanyBoost Target$51.00 ➝ $57.00
11/5/2020Robert W. BairdBoost TargetBuy ➝ Outperform$52.00 ➝ $58.00
11/5/2020Piper SandlerBoost TargetOverweight$50.00 ➝ $57.00
11/5/2020Needham & Company LLCBoost TargetBuy$57.00 ➝ $62.00
10/23/2020GuggenheimInitiated CoverageBuy$77.00
10/12/2020Leerink PartnersBoost TargetOutperform$59.00 ➝ $60.00
9/2/2020Robert W. BairdInitiated CoverageOutperform$52.00
8/10/2020Morgan StanleyBoost TargetOverweight$42.00 ➝ $53.00
8/7/2020Leerink PartnersBoost TargetOutperform$48.00 ➝ $59.00
8/3/2020Needham & Company LLCReiterated RatingBuy$48.00 ➝ $57.00
7/27/2020Piper SandlerReiterated RatingBuy$45.00
7/22/2020Leerink PartnersBoost TargetOutperform$45.00 ➝ $48.00
7/13/2020Needham & Company LLCReiterated RatingBuy$48.00
6/5/2020Wells Fargo & CompanyBoost TargetOverweight$40.00 ➝ $42.00
5/6/2020Morgan StanleyBoost TargetOverweight$36.00 ➝ $42.00
4/21/2020Piper SandlerLower TargetOverweight$48.00 ➝ $44.00
(Data available from 4/19/2020 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 13 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 6 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2025

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Axonics logo
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
Read More

Today's Range

Now: $70.98
Low: $70.98
High: $70.98

50 Day Range

MA: $70.61
Low: $69.66
High: $70.98

52 Week Range

Now: $70.98
Low: $66.32
High: $71.05

Volume

N/A

Average Volume

410,776 shs

Market Capitalization

$3.63 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82

Frequently Asked Questions

What sell-side analysts currently cover shares of Axonics?

The following Wall Street sell-side analysts have issued research reports on Axonics in the last year: Needham & Company LLC.
View the latest analyst ratings for AXNX.

What is the current price target for Axonics?

0 Wall Street analysts have set twelve-month price targets for Axonics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Axonics in the next year.
View the latest price targets for AXNX.

What is the current consensus analyst rating for Axonics?

Axonics currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AXNX, but not buy more shares or sell existing shares.
View the latest ratings for AXNX.

What other companies compete with Axonics?

Other companies that are similar to Axonics include Solventum, Smith & Nephew, Penumbra, Stevanato Group and Glaukos. Learn More about companies similar to Axonics.

How do I contact Axonics' investor relations team?

Axonics' physical mailing address is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. The company's listed phone number is (949) 396-6322 and its investor relations email address is [email protected]. The official website for Axonics is www.axonics.com. Learn More about contacing Axonics investor relations.